PTO/SB/05 (12/97)
Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# UTILITY PATENT APPLICATION TRANSMITTAL

*(Only for new nonprovisional applications under 37 CFR 1.53(b)*

| *Attorney Docket No.* 00177/522457 KH-DIV | *Total Pages :* |
|---|---|
| *First Named Inventor or Application Identifier* Saiko HOSOKAWA et al. | |
| *Express Mail Label No.:* | |

jc678 U.S. PTO 09/467903 12/21/99

jc678 U.S. PTO 12/21/99

## APPLICATION ELEMENTS

*See MPEP chapter 600 concerning utility patent application contents.*

*ADDRESS TO:* Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. [X] Fee Transmittal Form
*(Submit an original, and a duplicate for fee processing)*

2. [X] Specification *[Total Pages -66]*
*(preferred arrangement set forth below)*
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. [X] Drawing(s) *(35 USC 113)* *[Total sheets -4]*
4. [X] Oath or Declaration *[Total Pages - 2]*
a.1. [] Newly executed (original or copy)
a.2. [] Unexecuted
b. [X] Copy from a prior application (37 CFR 1.63(d))
*(for continuation/divisional with Box 17 completed)*
***[Note Box 5 below]***
i. [] DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

5. [X] Incorporation By Reference
*(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. Microfiche Computer Program *(Appendix)*

7. []Nucleotide and/or Amino Acid Sequence Submission
*(if applicable, all necessary)*
a. [] Computer Readable Copy
b. [] Paper Copy (identical to computer copy)
c. [] Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8. [] Assignment Papers (cover sheet & document(s))
9. [] 37 CFR 3.73(b) Statement [] Power of Attorney
*(when there is an assignee)*
10. [] English Translation Document *(if applicable)*
11. [X] Information Disclosure Statement (IDS)/PTO-1449
[] Copies of IDS Citations
12. [X] Preliminary Amendment
13. [X] Return Receipt Postcard (MPEP 503)
*(Should be specifically itemized)*
14. [] Small Entity Statement(s)
[] Statement filed in prior application, Status still proper and desired
15. [] Certified Copy of Priority Document(s)
*(if foreign priority is claimed)*
16. [X] Other - Claim of Priority
Declaration (with reference)

17. If a CONTINUING APPLICATION, *check appropriate box and supply the requisite information:*
[] Continuation [X] Divisional [] Continuation-in-part (CIP) of prior Application No.

## 18. CORRESPONDENCE ADDRESS


WENDEROTH, LIND & PONACK
2033 "K" Street, N.W.
Suite 800
Washington, D.C. 20006
Phone:(202) 721-8200
Fax:(202) 721-8250


December 21, 1999

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Saiko HOSOKAWA et al.

By _____
Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/dln
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006
Telephone (202) 721-8200
December 21, 1999

[Check No. 36169 ]
99-1372

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Saiko HOSOKAWA et al. :

Serial No. NEW : **Attn: Application Branch**

Filed December 21, 1999 : **Attorney Docket No. 00177/522457 KH-DIV**

HUMAN MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO SURFACE ANTIGEN OF CANCER CELL MEMBRANE **(this is a divisional application of Serial No. 08/450,363, filed May 25, 1995, now pending, which is a divisional application of Serial No. 08/360,125, filed December 20, 1994, now patented as U.S. Patent 5,767,246, which is a Continuation Application of Serial No. 07/905,534, filed June 29, 1992, now abandoned.)**

[Examiner R. Schwadron

[Group Art Unit 1644]

---

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Please amend the above-identified application as follows:

**In the Specification**:

Page 1, immediately below the title and above line 3, please insert:

--BACKGROUND OF THE INVENTION

1. Field of the Invention--;

between lines 9 and 10, insert:

--2. Description of Related Art--.

Page 2, line 5, after "drawbacks" insert --in--;

line 7, after "and" insert --in--.

Page 3, between lines 18 and 19, insert:

--SUMMARY OF THE INVENTION--.

Page 5, line 3, delete in its entirety and insert in its stead:

--BRIEF DESCRIPTION OF THE DRAWINGS--;

between lines 14 and 15, insert:

--DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT--.

Page 10, line 13, change "phsphatidylcholine" to --phosphatidylcholine--.

Page 12, line 3, change "antiobody" to --antibody--;

line 22, change "9331/1989" to --9931/1989--.

Page 20, line 7, change "limphocyte" to --lymphocyte--;

line 18, change "limphocyte" to --lymphocyte--;

line 26, change "limphocyte" to --lymphocyte--.

Page 21, line 17, change "meshes" to --mesh--;

line 18, change "meshes" to --mesh--;

line 20, change "meshes" to --mesh--.

Page 23, line 9, change "coloured" to --colored--.

Page 24, line 10, change "Purification Kit" to --PURIFICATION KIT--.

Page 25, line 7, change "Thermal Cycler" to --THERMAL CYCLER (PCR apparatus)--;

line 16, after "IgGs" insert --shown in Sequence Listing No. 1--;

line 22, after "region" insert --shown in Sequence Listing No. 2--.

Page 34, line 9, change "Purification Kit" to --PURIFICATION KIT--; after "(" insert --kit for purifying mRNA mfd. by--.

Page 37, line 6, change "polyethylene/glycol" to --poly(ethylene glycol)--.

Page 39, line 23, change "Sepharose" to --SEPHAROSE--; after "(" insert --gel filtration medium mfd. by--.

**In the Sequence Listing**:

Please transfer the paper and computer-readable copies of the sequence listing from the parent application Serial No. 08/450,363 filed May 25, 1995, to the present application. The sequence listing of the present application is identical to the parent application, and the paper and computer-readable copies of the sequence listing in the parent application are identical to each other. No new matter was added to the sequence listing in the parent application, and thus, no new matter is added to the sequence listing of the present application.

Please renumber the pages of the Claims and Abstract to pages 105-110.

**In the Claims**:

Kindly cancel claims 1-29 without prejudice.

Kindly add the following new claims:

--30. A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,

said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.

31. The pharmaceutical composition of claim 30, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.

32. The pharmaceutical composition of claim 30, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.

33. The pharmaceutical composition of claim 30, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.

34. The pharmaceutical composition of claim 30, wherein the monoclonal antibody fragment is a $F(ab')_2$ antibody fragment.

35. A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,

said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane,

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.

36. The pharmaceutical composition of claim 35, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.

37. The pharmaceutical composition of claim 35, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.

38. The pharmaceutical composition of claim 35, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.

39. The pharmaceutical composition of claim 35, wherein the monoclonal antibody fragment is a $F(ab')_2$ antibody fragment.

40. A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,

said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.

41. The liposome/antibody conjugate of claim 40, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.

42. The liposome/antibody conjugate of claim 40, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.

43. The liposome/antibody conjugate of claim 40, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.

44. The liposome/antibody conjugate of claim 40, wherein the monoclonal antibody fragment is a $F(ab')_2$ antibody fragment.

45. A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,

said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.

46. The liposome/antibody conjugate of claim 45, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.

47. The liposome/antibody conjugate of claim 45, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.

48. The liposome/antibody conjugate of claim 45, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.

49. The liposome/antibody conjugate of claim 45, wherein the monoclonal antibody fragment is a $F(ab')_2$ antibody fragment.--

## REMARKS

The present paper is presented concurrently with the filing of the above-identified divisional application.

For calculation of the filing fee, claims 1-29 have been cancelled and replaced with new claims 30-49. Thus, no additional claims fee is necessary.

The specification has been amended as in the parent application.

Applicants respectfully request favorable reconsideration in view of the following remarks, which were presented in the parent application. Applicants have reiterated the following remarks to preserve the comments of record from the parent application.

In support of the remarks contained hereinbelow, a Declaration from the parent application has been submitted under 37 C.F.R. 1.132.

Applicants again request the Examiner to review the enclosed Declaration and reference which demonstrates the usefulness of antibody fragment $F(ab')_2$ in "targeting therapy".

Applicants believe that the specification clearly teaches one skilled in the art how to use the claimed antibody fragments, such as Fab'. Further, Applicants also strongly believe that it is well known to one skilled in the art how to use other antibody fragments, such as $F(ab')_2$ in view of the state of the art at the time of the priority date of the present application.

Based on the Examainer's comments, from the parent application, the Examiner believes that the use of the term "antibody fragment" encompasses subject matter which includes antibody fragments such as Fv, Fd, or $F(ab')_2$, which is not described in the specification. However, Applicants strongly believe that the specification clearly describes how to use Fab' fragments in the present invention, and how to use $F(ab')_2$ fragments for the purpose of the present invention.

It is well established in patent law that the specification does not need to literally describe "in ipsis verbis" the particular claim language in order for the specification to satisfy the written

description requirement of 35 USC § 112, first paragraph. See, for example, *In re Lukach* 169 USPQ 795, 796 (CCPA) 1971. Furthermore, it is sufficient that the specification "convey clearly to one skilled in the art, the information that the Applicant has invented the specific subject matter claimed". See, for example, *In re Wertheim* 191 USPQ 90, 96 (CCPA 1976) and *In re Ruschig* 154 USPQ 118, 123 (CCPA 1967).

It is appropriate for the claims to utilize claim language which does not readily appear in the specification as long as one skilled in the art would impliedly or inherently recognize that the Applicant has invented the specific subject matter claimed. In reviewing the teachings of the specification set forth on pages 1, 3, 12, 36, 37 and 41, it is clear that the inventors did contemplate a pharmaceutical composition or a liposome/antibody conjugate comprising an antibody fragment of the monoclonal antibody.

The specification teaches on page 11, line 18 to page 12, line 17 the method for binding an antibody to the surface of a liposome. It discloses as a preferred method a reaction of a thiolated antibody with a maleimide group existing in a liposome (see page 11, lines 21-24). As methods for thiolation, it teaches (1) the use of SPDP, iminothiolane (methyl-4-mercaptobutyrimidate), or mercaptoalkylimidate, which is conventionally used for thiolation of proteins (page 11, lines 21-24), and (2) reduction of the dithiol group intrinsic to an antibody (page 12, lines 6-9).

The second method (2) mentioned above comprises the use of the thiol group possessed by a Fab' antibody fragment which is formed by the reduction of a $F(ab')_2$ fragment as disclosed on page 12, lines 9-13 and page 36, line 16, page 37, line 5 (Section a. of Example 7) of the specification.

On the other hand, the first method (1) mentioned above, which is addressed to **thiolation of a protein having no thiol group, like $F(ab')_2$** is carried out in a conventional manner as described, for example, by Wright, S. et al., Advanced Drug Delivery Reviews, 3 (1989), pp. 343-352 (see especially on page 351, lines 18-22 and Table II), and by Traut, R.R. et al., Biochemistry, 12 (1973), p 3266-3273, copies of which have already been made of record in the parent application. Applicants have also demonstrated from the Declaration of T. Tagawa (Appendix III submitted January 26, 1998) that an Experiment conducted using an antibody-bonded PEG-modified liposome which was prepared by binding $F(ab')_2$ to a liposome in accordance with the above-mentioned Traut's method is clearly well within the state of the art at the time of the priority date and clearly show that the present inventors contemplated the present invention using other antibody fragments such as Fab' and $F(ab)_2$.

Applicants wish to remind the Examiner that the antibody fragments of the present invention must contain an antigen binding site for the purpose of the present invention. The current claims recite that the monoclonal antibody fragments must be bound to the surface of a liposome enclosing an anti-cancer agent or toxin and be capable of specifically binding to a surface antigen of a stomach and colon cancer cell membrane. Accordingly, the antibody or fragment thereof used in the claimed invention is defined by specific amino acid sequences.

Applicants also wish to advise the Examiner that the gist of the present invention resides in the finding of a specific monoclonal antibody defined by the amino acid sequences listed in the Sequence Listing, which can actually bind to the aimed antigen, and not in the finding that antibody fragments can also be used in the same manner as the antibodies themselves for the

purpose of the present invention. In other words, it is not necessary under U.S. practice for the present application to teach what is already widely known or recognized by those skilled in the art as of the priority date of the present application. Since it is well known to one skilled in the art that antibody fragments in the field of "targeting therapy" are used in the same manner as the antibody themselves, it clearly shows that the inventors contemplated the use of such fragments, as well as the antibodies themselves in the field of "targeting therapy". In support thereof, Applicants have submitted Dr. Hosokawa's Declaration in which the usefulness of antibody fragment $F(ab')_2$ in "targeting therapy" is experimentally shown. Further, a copy of the reference, Biochimica et Biophysica Acta (880 (1986) p72-77), which teaches the usefulness of $F(ab')_2$ in "targeting therapy" (see, in particular, Abstract of the article), as well as demonstrates that the use of $F(ab')_2$ in "targeting therapy" was already widely known and recognized by those skilled in the art as of the priority date of the present application. In other words, the enclosed Declaration and reference clearly demonstrate that the use of antibody fragments in "targeting therapy" as contemplated by the inventors was well known to one skilled in the art at the time of the invention.

Thus, since it is clear that the present inventors contemplated the use of all antibody fragments capable of specifically binding to the surface antigen of stomach and colon cancer cells for "targeting therapy", Applicants respectfully submit that the application is now in condition for allowance. Such action is thus, respectively solicited.

If, however, the Examiner has any suggestions for expediting allowance of the application or believes that direct contact with the Applicants' attorney will advance the prosecution of this case, the Examiner is invited to contact the undersigned at the telephone number below.

Respectfully submitted,

Saiko HOSOKAWA et al.

By _____
Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/dln
Washington, D.C. 20006
Telephone (202) 721-8200
December 21, 1999

# Human Monoclonal Antibody Specifically Binding to Surface Antigen of Cancer Cell Membrane

The present invention relates to a novel human monoclonal antibody useful for diagnosis and therapy of cancer, an isolated DNA encoding the monoclonal antibody, and a hybridoma producing the antibody. The present invention also relates to an anti-cancer formulation comprising the antibody bonded to a liposome which contains an anti-cancer agent.

There has been no anti-cancer formulation thus far, which is sufficiently effective for the treatment of solid cancer. On the other hand, there has long existed an idea called "targeting" in which a therapeutical agent is concentrated at a tissue or an organ to be treated in order to maximize the therapeutical effect of the agent. Accordingly, it has been expected that focusing an anti-cancer agent at a cancer tissue by means of "targeting" may allow a therapy of the solid cancer. A number of trials to concentrate an anti-cancer agent or a toxin at a cancer tissue were made since a method for production of mouse monoclonal antibodies in large quantities has been established by Milstein and Köhler (Nature, 1975), and some of them were successful.

Thus far, binding of an antibody to a therapeutic agent has been accomplished by directly binding an antibody to a chemically-modified therapeutic agent, or indirectly binding them via a water-soluble polymer such as dextran. These methods, however, have drawbacks that the amount of a therapeutic agent capable of binding to one antibody molecule is very limited, and that chemical modification of a therapeutic agent often causes lowering of the therapeutical activity. As one of the countermeasures to overcome the drawbacks, there was proposed a new delivery system which consists of an antibody bonded to the surface of a liposome in which a therapeutic agent is encapsuled, and many favorable results were reported (Konno et al, Cancer Research 47 4471, 1987; Hashimoto et al, Japanese Patent Publication (unexamined) No. 134032/1983).

However, mouse monoclonal antibodies have a limited clinical use and continued administration thereof is impossible from a practical point of view due to side effects such as anaphylaxis caused by immune response (See A. Lo Bugli et al, Proc. Natl. Acad. Sci. U.S.A., 86 4220, 1989). Accordingly, human monoclonal antibodies rather than mouse monoclonal antibodies are preferable for the purpose of clinical use. However, preparation of human monoclonal antibodies which adequately react with cancer cells has long been considered very difficult because of

the reasons that it is very difficult to conduct passive immunity for the purpose of obtaining human B cells which produce a desired antibody, and that any efficient methodology which allows infinite reproduction of antibody-producing cells has not been established yet.

In such a situation as mentioned above, the inventors of the present invention have made extensive study for the purpose of obtaining a human monoclonal antibody which permits "targeting therapy" on cancer tissue or organ with the help of anti-cancer agents or toxins, and they have succeeded in preparing a hybridoma capable of producing a novel human monoclonal antibody, the antigen to which exists on the surface of cell membrane of cancer cells. They also have succeeded in preparing a therapeutical formulation useful for "targeting therapy" of cancer, by binding the monoclonal antibody of the invention to a liposome in which an anti-cancer agent is encapsuled. The present invention is based on these findings.

Thus, the present invention provides a human monoclonal antibody specific to an antigen existing on the surface of a cancer cell membrane, said monoclonal antibody being produced by a fused cell between a lymphocyte derived from cancer patient and a mouse myeloma cell. The invention further provides an isolated gene encoding the

antibody, a hybridoma producing the antibody, and an anti-cancer formulation containing the antibody.

The human monoclonal antibodies of the present invention contain, in the variable region of the heavy chain, the amino acid sequences shown, for instance, in Sequence Listing Nos. 13, 14, and 15. More specifically, the monoclonal antibodies of the invention include, among others, those in which the variable region of the heavy chain comprises the amino acid sequences shown in Sequence Listing Nos. 16, 17, and 18, and the variable region of the light chain comprises the amino acid sequences shown in Sequence Listing Nos. 19, 20, and 21, and those in which the variable region of the heavy chain comprises the amino acid sequences given in Sequence Listing Nos. 22, 23, and 24, and the variable region of the light chain comprises the amino acid sequences given in Sequence Listing Nos. 25, 26, and 27.

The monoclonal antibodies of the invention include any variants of the above-mentioned specific antibodies, which are obtainable by making insertion, deletion, substitution and/or addition of one or more amino acid residues to the amino acid sequences of the above-identified antibodies with the limitations that such modification must not adversely affect the reactivity of

the antibodies against the antigens. The present invention will be more detailed below.

In the accompanying drawings;

Fig. 1 schematically shows the construction of vector pKCRD.

Fig. 2 schematically shows the construction of vector pKCR(ΔE)/H.

Fig. 3 shows reactivity of antibody 1-3-1 to colon cancer cell line C-1.

Fig. 4 shows reactivity of antibody 1-3-1 to gastric cancer cell line MKN45.

Fig. 5 shows anti-cancer effects of adriamycin-containing and PEG-modified liposome bonded to antibody GAH on the cancer transplanted to nude mouse.

The hybridoma producing a human monoclonal antibody of the invention is prepared according to the method described by A. Imam (Cancer Research 45 263, 1985). Thus, lymphocytes which have been isolated from extracted lymph node associated with cancer are fused with mouse myeloma cells in the presence of polyethylene glycol. Hybridomas thus obtained are screened by means of enzyme immunoassay using various cancer cell line fixed with paraformaldehyde, and hybridomas capable of producing antibodies are obtained and cultured. From supernatant of the resulting culture, monoclonal antibodies are isolated

and purified according to a conventional method such as disclosed by R. C. Duhamel (J. Immunol. Methods 31 211, 1979).

The purified monoclonal antibody is labelled with a fluorescent substance and examined about its reactivity with living cancer cells and normal cells such as erythrocytes and leucocytes using Flow Cytometry. Hybridoma producing an antibody which reacts with the living cells but not with normal cells are selected. Alternatively, the reactivity of antibodies to cancer cells isolated from cancer tissue of a patient is compared with the reactivity to normal cells derived from non-cancer segment of the same organ, and a hybridoma producing an antibody which reacts with the cancer cell and does not react, or reacts as moderately as an antibody derived from normal volunteer, with normal cells, is selected.

A base sequence of a DNA encoding a human monoclonal antibody produced by the hybridoma selected above can be determined in the following manner.

In accordance with Casara et al method (DNA 2 329, 1983), mRNAs are separated from the antibody-producing hybridoma cells, using guanidine thiocyanate-lithium chloride, and cDNA library is prepared by the use of oligo (dT) primer. The cDNAs thus obtained are then subjected to (dG) tailing. Consensus sequence between poly C capable of

hybridizing with the dG tail obtained above and an already available human gene encoding heavy or light chain of human antibodies is used as a probe for amplification of the antibody-encoding cDNA by means of PCR. The terminal of the amplified DNA is made blunt. The DNA separated from an electrophoresis gel is inserted to a cloning vector such as pUC119, and the base sequence of the DNA is determined by Sanger et al dideoxy method (Proc. Natl. Acad. Sci. U.S.A. 74 5463, 1977).

Preferable antibodies of the present invention are those in which the variable region of the heavy chain comprises the amino acid sequences shown in Sequence Listing Nos. 13, 14, and 15. Specific examples of preferred antibodies are, among others, those in which the variable region of the heavy chain comprises the amino acid sequences shown in Sequence Listing Nos. 16, 17, and 18, and the variable region of the light chain comprises the amino acid sequences shown in Sequence Listing Nos. 19, 20, and 21, and those in which the variable region of the heavy chain comprises the amino acid sequences shown in Sequence Listing Nos. 22, 23, and 24, and the variable region of the light chain comprises the amino acid sequences shown in Sequence Listing Nos. 25, 26, and 27.

The above-noted amino acid sequences in Sequence Listing Nos. 13, 14, and 15; 16, 17, and 18; and 22, 23,

and 24 are called "hyper variable region" in variable region of the heavy chain. Likewise, the amino acid sequences in Sequence Listing Nos. 19, 20, and 21; 25, 26, and 27 are called "hyper variable region" in variable region of the light chain. These regions are responsible for the specificity of the antibody and determinative to binding affinity between the antibody and the antigenic determinant. Accordingly, the variable region of the heavy chain in the antibodies of the invention can have various amino acid sequences derived from different antibodies so far as it comprises the above-mentioned hyper variable regions.

The most preferred monoclonal antibodies of the invention are those in which the variable regions of the heavy and light chains are represented by the amino acid sequences of Sequence Listing Nos. 5 and 6 respectively, and also 11 and 12 respectively. The DNA sequences encoding constant regions of the heavy and light chains are the same as those disclosed in Nucleic Acids Research 14 1779, 1986, The Journal of Biological Chemistry 257, 1516, 1982 and Cell 22, 197, 1980, respectively.

The monoclonal antibody of the invention may be prepared by culturing the hybridoma producing the antibody of the invention in eRDF or RPMI1640 medium containing fetal bovine serum. Alternatively, it may also be prepared

by connecting the DNAs having the base sequences in Sequence Listing No. 3, 4, 9 and No. 10, which encode variable regions of heavy and light chains respectively, with known DNAs encoding the constant regions as mentioned above to obtain a pair of genes encoding the monoclonal antibody of the invention, inserting the genes into one of various known expression vectors, transforming an appropriate host cell such as CHO cell with the expression vectors, and culturing the resultant transformant. As expression vectors to be used in animal cells, there may conveniently used a combination of pKCR (ΔE)/H and pKCRD which may be constructed in the manner as shown in Figs. 1 and 2 starting from pKCRH2 disclosed by Mishina (Nature 307 605,1984). In more detail, a gene encoding the heavy chain, to which a HindIII restriction site has been added, is inserted into plasmid pKCR (ΔE/H) at the HindIII site, and a selective marker such as DHFR gene is inserted into the plasmid at SalI site. On the other hand, a gene encoding the light chain, to both ends of which EcoRI restriction site has been added, is inserted into plasmid pKCRD at EcoRI site, and then the DHFR gene is also inserted into the plasmid at SalI site. Both of the plasmids obtained above are incorporated into a host cell such as CHO dhfr$^-$ (Urlaub G. & Chasin L. A., Proc. Natl. Acad. Sci. U.S.A., 77 4216, 1980) by means of calcium

phosphate method. The resultant transformant is cultured in αMEM medium containing no nucleotide, and grown cells are subjected to further selection for antibody-producing clones. The antibody of the invention can be obtained and purified by culturing the selected clone, adsorbing the resulting supernatant to a column filled with Protein A supported by cerulofine or agarose, and eluting the antibody from the column.

A liposome used for the preparation of the anti-cancer formulation of the invention is composed of two lipid layers. The lipid layer may be of monolayer or multiple layers. Constituents of the liposome are phsphatidylcholine, cholesterol, phosphatidylethanolamine, etc. Phosphatidic acid, which provides the liposome with electric charge, may also be added. The amounts of these constituents used for the production of the liposome are, for instance, 0.3-1 mol, preferably 0.4-0.6 mol of cholesterol, 0.01-0.2 mol, preferably 0.02-0.1 mol of phosphatidylethanolamine, 0.0-0.4 mol, preferably 0-0.15mol of phosphatidic acid per 1 mol of phosphatidylcholine.

The liposome used in the present invention may be prepared by conventional methods. For example, a mixture of the above-mentioned lipids, from which the solvents have been removed, is emulsified by the use of a homogenizer, lyophilized, and melted to obtain multilamera liposome.

Adjustment of particle size of the resultant liposomes may be conducted by ultrasonication, high-speed homogenization, or pressure filtration through a membrane having uniform pore size (Hope M. J. et al., Biochimica et Biophysica Acta 812 55, 1985). Preferable particle size of the liposomes are between 30nm and 200nm.

Anti-cancer agents encapsuled in the liposome includes carcinostatic agents such as adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, and aclacinomycin, toxins such as ricin A and diphtheria toxin, and antisense RNA. Encapsulation of anti-cancer agent into liposome is accomplished by hydration of the lipids with an aqueous solution of the anti-cancer agent. Adriamycin, daunomycin, and epirubicin may be encapsulated into a liposome by means of remote loading method taking advantage of pH gradient (Lawrence D.M. et al., Cancer Research 49 5922, 1989).

Binding of a monoclonal antibody to the surface of the liposome mentioned above may be accomplished by the formation of cross-linkage between phosphatidylethanolamine and the antibody using glutaraldehyde. However, preferred method is that a thiolated antibody is allowed to react with a liposome comprising a lipid into which a maleimide group has been incorporated. Remaining maleimide groups on the surface of the liposome may be further reacted with a

compound containing thiolated polyalkyleneglycol moiety, thereby the surface of the liposome is modified.

Thiolation of an antiobody may be conducted by the use of N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), which is usually used for thiolation of protein, iminothiolane, or mercaptoalkylimidate. Alternatively, a dithiol group intrinsic to an antibody may be reduced to form a thiol group. The latter is preferred from the view point of keeping antibody's function. Another method to provide an antibody with a thiol group is that an antibody is treated with an enzyme such as pepsin to form $F(ab)'_2$, which is then reduced with dithiothreitol (DTT) to form Fab', which gives one to three thiol groups.

The binding of the thiolated antibody to the maleimide group-containing liposome may be accomplished by reacting them in a neutral buffer solution at pH6.5-7.5 for 2-16 hours.

The anti-cancer formulation of the present invention may be prepared by means of conventional methods such as dehydration method (Japanese Patent Publication No. 502348/1990) and lyophilization method (Japanese Patent Publication No. 9331/1989).

The anti-cancer formulation of the invention may be administered intravascularly, peritoneally, or locally. Dosage of the formulation varies depending on the nature of

particular anti-cancer agent encapsulated into the liposome. When the agent is adriamycin, the dosage is the one corresponding to adriamycin 50mg or less/kg body weight, preferably 10mg or less/kg, more preferably 5mg or less/kg.

The following detailed examples are presented by way of illustration of certain specific embodiments of the present invention.

Example 1

Establishment of Hybridoma Producing Human Monoclonal Antibody GAH

Hybridoma producing human monoclonal antibody GAH was established by cell fusion between lymphocytes derived from a lymph node associated with cancer tissue of a patient and mouse myeloma cells.

(1) Preparation of Lymphocytes

Cancer-associated lymph node extracted from a patient suffering from colon cancer was cut up into fine pieces with scissors and scalpel, and cells were dispersed using a stainless net in Culture Medium A (eRDF (Kyokuto Seiyaku Kogyo) + 50μg/ml gentamicin sulfate). The resultant cell suspension was centrifuged at 1000 rpm for 10 minutes and the supernatant was discarded. The residue was suspended in fresh Culture Medium A, and the suspension was centrifuged again to obtain $2.6 \times 10^7$ cells.

(2) Cell Fusion

The lymphocyte cells obtained above were subjected to cell fusion with mouse myeloma cells ($1\times10^7$) in the presence of polyethyleneglycol (Boehringer-Mannheim) according to a conventional method. The fused cells were suspended into Culture Medium A added with 10μM hypoxanthine, 0.04μM aminopterin, 1.6μM thymidine, and 10% fetal calf serum (FCS), said medium being referred to as HAT addition medium hereinafter, so that the density of the lymphocytes may be $5.4\times10^5$/ml. The suspension was plated on 96 well plates at 100μl/well and cultured at 37°C in a $CO_2$ incubator. Half of the culture medium was substituted with HAT addition medium from time to time and the cultivation was continued until hybridoma's colonies appeared. The hybridoma's colonies were observed in all of the wells. The supernatant of the culture in each well was tested on the reactivity to several established cancer cell lines such as colon cancer cell line C-1 (Sato et al, Igakunoayumi (Progress of Medicine) 96 876, 1976, obtained from Men Eki Seibutsu Kenkyusho (Institute of Immunized Organisms)), and stomach cancer cell line MKN45 (Naito et al, Gan to Kagaku Ryoho (Cancer and Chemotherapy) 5 89, 1978, obtained from above-noted Institute) according to the method described in Experiment 1. Positive wells were 7.3% (35 wells) against C-1 and 4.6% (22 wells) against MKN45,

and 6 wells showed positive reaction to both strains. Cloning of hybridomas was conducted using the wells which showed positive reaction to both lines. The cloning was conducted three times by means of limiting dilution method, and hybridoma clone GAH was established.

Example 2

Purification and Labeling of Monoclonal Antibody GAH

(1) Culture of Hybridoma GAH and Purification of Monoclonal Antibody GAH

Fetal calf serum was passed through a Protein A-agarose (RepliGen), thereby substances adsorbed to the column was removed from the serum. For culture of hybridoma GAH, eRDF culture medium (Kyokuto Seiyaku) to which 3% of the above serum had been added was used. The culture of hybridoma GAH was then charged into a Protein A-agarose column, and adsorbed antibody was then eluted out to obtain purified antibody. The use of the above-noted serum allowed to obtain pure antibody GAH free from other antibodies of serum origin and substances adsorbed to Protein A-agarose. The antibody GAH was confirmed to be a pure IgG by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

(2) Fluorescent Labeling of Antibody GAH

The purified antibody GAH was labeled by fluorescein isothiocyanate (FITC) according to the method of Coons A. H. Thus, the antibody was dialyzed against a carbonate buffer solution (pH9.5) and reacted with FITC solution. The labeled antibody was separated from free FITC by gel filtration. Absorbance of fractions containing labeled antibody was measured at $OD_{280nm}$ and $OD_{495nm}$ and labeling degree was determined. The binding molar ratio of the antibody and FITC (F/P ratio) was 0.93.

Experiment 1

Study on Reactivity of Human Monoclonal Antibody against Cancer Cell Lines

(1) Cancer Cell Lines and Preservation Thereof

Colon cancer cell line C-1 and stomach cancer cell line MKN45 were used as human cancer cell lines. The cells were preserved and grown at 37°C under 5% $CO_2$ conditions using Culture Medium B (eRDF medium containing 10% FCS).

(2) Study on Reactivity to Cancer Cell Lines

a. Determination of reactivity against solid cancer cell lines

Cancer cells were cultured until monolayer in a 96 well plate for 3 or 4 days. After removal of culture supernatant, the plate was washed twice by 10mM phosphate buffer (pH7.4) and 0.15M NaCl solution (PBS), and 2% paraformaldehyde fixation was conducted at room temperature

for 20 minutes. After washing 5 times with PBS, PBS solution containing 5% BSA (bovine serum albumin) was added to wells (200μ/well), and the plate was kept 37°C for 2 hours to complete blocking. The plate was washed 5 times with PBS, and 50μl of culture supernatant of hybridoma was added thereto. After two hour reaction at 37°C, the plate was washed 5 times with PBS and 50μl of alkaliphosphatase conjugated goat antibody to human antibody (1000 dilution, Capel) was added. Following one hour reaction at 37°C, the plate was washed 5 times with PBS and added with 0.05M carbonate buffer - 1mM MgCl (pH9.5) containing 25mM p-nitrophenyl phosphate at ratio of 50μl/well and allowed to react at room temperature for one hour to overnight. Absorbance at 405nm was measured with micro-plate photometer (Colona). Reactivity was determined according to the method described in Example 1 (2). Cloning from the wells in which positive reaction against cultured cancer cell lines C-1 and MKN45 has been observed gave hybridoma GAH. Purified antibody from culture supernatant of GAH showed the same reactivity.

b. Reactivity to living cancer cells

Cancer cells were cultured in a flask or Petri dish and culture supernatant was discarded. To the residue was added a PBS solution containing 0.02% EDTA, and the mixture was left to stand at room temperature for 30

minutes allowing the cells to float. The cells were washed with Culture Medium B by centrifugation and suspended in healthy human serum containing the fluorescent-labeled antibody GAH (final concentration: 50μg/ml) obtained in Example 2 (2) so that cell density of about $1\times10^6$/200μl may be obtained, and the suspension was allowed to react at 0°C for 60 minutes. The suspension was centrifuged at 2000 rpm for 2 minutes and the supernatant was discarded. The remaining cells were suspended in 1ml of PBS, washed by centrifugation, and resuspended in 300μl of PBS containing 10μg/ml of propidium iodide (PI). The suspension was subjected to the observation by flow cytometer (FCM), FACS440 (Becton Dickinson), in order to determine the magnitude of fluorescence (FITC and PI) bonded to particular cell. Dead cells having PI fluorescence could be removed because the dead cells took in PI in the nucleic acids and emitted PI fluorescence. Markers having five standard amounts of fluorescence (quantitative kit: Ortho Diagnostic Systems) were subjected to FCM under the same conditioned as above. Based on the markers, average binding amount of FITC per cell was calculated. On the basis of the average binding amount and F/P ratio of labeled antibody, an average number of antibodies bonded to one living cell was determined. The results are shown in Table 1.

Table 1

| Cancer Cell Strain | Antibody | |
|---|---|---|
| | GAH | Control IgG |
| MKN45 | $3.5\times10^4$ | $0.15\times10^4$ |
| C-1 | $0.6\times10^4$ | $<0.1\times10^4$ |

When compared with IgG derived from healthy human serum, which was labeled by fluorescence in the same manner as GAH and used as a control, about 6-23 times larger amount of antibody GAH has bonded to stomach and colon cancer cells.

Experiment 2

Reactivity of Human Monoclonal Antibody GAH to Blood Cells

Erythrocytes were separated from peripheral blood taken from 7 healthy volunteers and 3 patients suffering from cancer according to Kinoshita's method (Separation of Erythrocytes; New Edition of Nippon Ketsuekigaku Zensho 13 800, 1979).

Leukocytes were obtained in the following manner: Peripheral blood was drawn from healthy volunteers with addition of heparin. 2ml of 6% dextran-physiological saline was added and mixed to 10ml of the blood. The mixture was left to stand at room temperature for 50 minutes to give a plasma layer, which was then separated

and centrifuged at 1500 rpm for 5 minutes to obtain leukocytes.

Reactivities of the monoclonal antibody of the invention to these blood cells were determined by means of FCM in the same manner as in the living cancer cells except that PI was not added. In this connection, the leukocytes were divided into limphocyte (major leukocyte cell), granulocyte, monocyte, and platelet, based on front and side light scattering in FCM (Bio/Technology 3 337, 1985), and reactivities to respective cells were separately determined. The test results were shown in Table 2.

Table 2

| Cells | Antibody | |
|---|---|---|
| | GAH | Control IgG |
| Leukocyte | | |
| limphocyte | negative | negative |
| granulocyte | $0.49\times10^4$* | $0.48\times10^4$* |
| monocyte | $0.41\times10^4$* | $0.43\times10^4$* |
| platelet | negative | negative |
| Erythrocyte | negative | negative |

*: Average number of antibodies bonded per cell

Antibody GAH showed no reaction to erythrocyte and limphocyte, while the reactivity to granulocyte and

monocyte was the same level as the reactivity to control IgG likewise in Experiment 1.

Experiment 3

Reactivity of Human Monoclonal Antibody GAH to Cells Derived from Fresh Cancer Tissue and Non-Cancer Tissue

In order to study a binding specificity of antibody GAH to cancer cells, normal cells were simultaneously isolated from fresh tissue belonging to the same organ of the same patient from which cancer cells were obtained, and reactivities of antibody GAH to respective cells were determined. Isolation of cells from the tissue was conducted according to Tokita's method (Ganno Rinsho (Cancer in Clinic) 32 1803,1986).

Thus, the tissue extracted was placed on Teflon sheet spreaded on a rubber plate, cut with a razor into fine pieces, and transferred onto a 1mm stainless meshes. The meshes was shaken in a Petri dish full of a culture medium to obtain the medium containing small cell aggregates which passed through the meshes. The medium was centrifuged at 1000 rpm, and floating fats and suspending necrotic debris were discarded. This centrifugation was repeated several times. The cell aggregates were subjected to pumping by means of a syringe with Cateran needle of 23 gauge to disperse the cells. The reactivity to the cells thus obtained was determined by FCM in the same manner as

in the living cancer cells. The test results are shown in Table 3.

Table 3

| Antibody | Colon | | Stomach | |
|---|---|---|---|---|
| | Cancer Cells | Non-cancer Cells | Cancer Cells | Non-cancer Cells |
| GAH | $1.1 \times 10^4$ | $0.03 \times 10^4$ | $180 \times 10^4$ | $4.6 \times 10^4$ |
| Control IgG | $0.15 \times 10^4$ | $0.04 \times 10^4$ | $3.5 \times 10^4$ | $0.9 \times 10^4$ |

Average number of antibodies bonded per cell

The average number of GAH antibodies bonded to cancer cells is remarkably higher than that in the non-cancer cells. In addition, the number of antibodies bonded to cancer cells was 51 times greater than that in the control IgG in stomach cancer, and 7 times greater in colon cancer. These results indicate that antibody GAH recognizes an antigen dominantly expressed on the surface of cell membrane of cancer cells.

Examples 3

(1) Determination of Subclass of Light Chain of Monoclonal Antibody GAH

Antibody GAH obtained in Example 2 (1) was subjected to SDS-PAGE in the reduced form. Heavy chain and

light chain separately electrophorated were blotted on a transmembrane (Polyvinylidene-dilluoride, Millipore). The membrane was blocked with 5% BSA solution and allowed to react with a goat antibody to human κ or λ chain, which was combined with peroxidase (Capel). After washing, a 0.05% (w/v) 4-chloronaphthol solution containing 0.015% $H_2O_2$ was allowed to react thereto as a substrate. The light chain of antibody GAH reacted with anti-human κ chain antibody, which was detected through the appearance of coloured band. This revealed that the light chain was κ chain.

(2) Preparation of Gene Encoding Monoclonal Antibody GAH

a. Preparation of cDNA encoding antibody GAH by means of polymerase chain reaction (PCR)

According to the method detailed below, poly(A)-containing RNAs were prepared from antibody GAH-producing hybridoma obtained in Example 1 (2) using guanidine thiocyanate-lithium chloride method (DNA 2 329, 1983).

The hybridoma cells ($1\times10^7$) were solubilized in a solution (7.5ml) comprising 5M guanidine thiocyanate, 10mM EDTA, 50mM Tris-HCl, pH7.0, and 8% (v/v) β-mercaptoethanol. To the mixture was further added and mixed cesium chloride to the final concentration of 1g/2.5ml. The solution (8.0ml) was gently overlayed on a 5.7M cesium chloride solution (3.5ml) in a centrifuge tube, and centrifuged at

30,000 rpm for 23.5 hours using Hitachi RPS40T Rotary, which gave RNAs as a precipitate. The precipitate was dissolved in a solution (400µl) comprising 0.1% sodium lauryl sulfate, 1mM EDTA, and 10mM Tris-HCl, pH7.5, followed by phenol-chloroform extraction and ethanol precipitation. The resultant RNAs (about 64µg) was dissolved in a solution (40µl) comprising 10mM Tris-HCl, pH8.0, and 1mM EDTA. A 21µl aliquot of the solution provided about 2.64µg of mRNA containing poly(A) by means of mRNA Purification Kit (Pharmacia). The poly(A)-containing mRNA (1.1µg) was dissolved in water (10µl). To the solution were added oligo d(T) 12-18 primer (1.5µg) (Pharmacia), 10mM 4 dNTP (3µl) (Takara Shuzo), reverse transcriptase (40U) (Life Science), RNase inhibitor (30U) (Takara Shuzo), 5 × reverse transcriptase buffer (6µl) comprising 250mM Tris-HCl, pH8.3, 40mM magnesium chloride, and 250mM potassium chloride, and additionally water to make a total volume of 30µl. The mixture was allowed to react at 41°C for one hour, followed by ethanol precipitation to obtain cDNA.

The cDNA thus obtained was dissolved in water (15.3µl). To the solution were added a 5 × terminal deoxynucleotide transferase buffer (4.8µl) (250mM Tris-HCl, pH7.5, 50mM magnesium chloride), terminal deoxynucleotide transferase (12U) (Pharmacia), and 10mM dGTP (2.4µl)

(Takara Shuzo) to make a total volume of 24µl, and the mixture was allowed to react at 37°C for 1.5 hours to add poly d(G) at 3′ terminal of cDNA. After completion of the reaction, the enzymes were inactivated by heating at 70°C for 15 minutes.

PCR was conducted based on the cDNA thus obtained as a template using Perkin Elmer Cetus DNA Thermal Cycler following the manual provided by the manufacturer. Thus, to the above reaction mixture (2µl) were added, as a primer for amplifying cDNA encoding variable region of the heavy chain, poly C (15 nucleotides) which hybridizes dG tail added to 3′ terminal of the cDNA (40pmol), a single stranded DNA primer (37 nucleotides) corresponding to the region spanning from part of the variable region (113-119 amino acid sequence in Sequence Listing No. 5) to the constant region which is common to all human IgGs (25pmol) (Nucleic Acids Research 14 1779, 1986), poly C as a primer for amplifying cDNA encoding variable region of the light chain (40pmol), a single stranded DNA primer (21 nucleotides) corresponding to the region spanning from J region of human κ chain (113-114 amino acid sequence of Sequence Listing No. 6) to the constant region (The Journal of Biological Chemistry 257 1516, 1982; Cell 22 197, 1980) (40pmol), 10 × PCR buffer (100mM Tris-HCl, pH8.3, 500mM potassium chloride, 15mM magnesium chloride, 0.1% (w/v)

gelatin (10µl), 10mM 4 dNTP (2µl) (Takara Shuzo), and Taq DNA polymerase (2.5U) (Takara Shuzo)), and further water to make a final volume of 100µl. Thirty cycles of incubations at 94°C for one minute (denaturing step) at 55°C for two minutes (annealing step) and at 72°C for three minutes (elongation step) were conducted and further incubation at 72°C for seven minutes was added. Reaction mixture was subjected to ethanol precipitation, and resultant precipitates were dissolved in water (30µl).

To the aqueous solution were added Klenow fragment (2U) (Takara Shuzo), 1mM 4 dNTP (4µl), and 10 × blunting buffer (500mM Tris-HCl, pH7.6, 100mM magnesium chloride) (4µl), 40µl in total, and the mixture was allowed to react at 37°C for 30 minutes to obtain a double-stranded cDNA having blunt ends.

b. Determination of base sequence of cDNA

The cDNA solution obtained above was subjected to 2% agarose electrophoresis, and a band was observed at about 500bp. The band was cut away from the agarose gel. The cDNA was inserted into a cloning vector pUC119 at SmaI site, and the base sequence was determined by dideoxy method, which revealed that among total base sequence of the PCR fragment, the base sequences encoding variable regions of the heavy and light chains were respectively those shown in Sequence Listing Nos. 3 and 4.

The amino acid sequences of variable regions of heavy and light chains of antibody GAH produced by the above-mentioned hybridoma were deduced from the base sequences determined above and are respectively shown in Sequence Listing Nos. 5 and 6. Based on the base sequences determined, antibody GAH was shown to belong to IgG1 subclass. The DNA fragment, the base sequence of which has been determined, can be prepared by means of DNA synthesizer with good reproducibility, and therefore, the acquisition of the DNA fragment does not require the repetition of the above procedure.

Example 4

Establishment of Human Monoclonal Antibody 1-3-1 Producing Hybridoma by Cell Fusion between Lymphocyte Derived from Cancer Associated Lymph Node and Mouse Myeloma

(1) Preparation of Lymphocyte

In substantial accordance with the procedure described in Example 1 (1), lymphocytes ($3\times10^7$) were prepared starting from cancer associated lymph node extracted from a patient with lung cancer.

(2) Cell Fusion

Lymphocyte cells obtained above were fused with mouse myeloma cells ($8\times10^6$) using polyethyleneglycol (Boehringer-Mannheim) according to the conventional method. In the same manner as Example 1 (2), the fused cells were

suspended in HAT addition medium to obtain cell density of $5.2\times10^5$/ml and placed on a 96 well plate at a ratio of 100µl/plate. Half of the culture medium was substituted with HAT addition medium from time to time and the culture was continued until hybridoma's colonies appeared. The hybridoma's colonies were observed in all of the wells. In the same manner as in Example 1 (2), the supernatant of the culture in each well was tested on the reactivity to fixed cancer cell lines such as colon cancer cell line C-1 and stomach cancer cell line MKN45, in accordance with the procedure described in Experiment 1 (2)-a. Positive wells were 16.3% (94 well) against C-1 and 6.3% (36 wells) against MKN45, and 4 wells showed positive reaction to both lines.

Cloning of hybridoma cells was conducted using the wells which showed positive reaction to both lines. The cloning was conducted three times by means of limiting dilution method, and hybridoma clone 1-3-1 was established.

Example 5

Purification and Labeling of Monoclonal Antibody 1-3-1

(1) Culture of Hybridoma 1-3-1 and Purification of Monoclonal Antibody 1-3-1

For culture of hybridoma 1-3-1, eRDF culture medium (Gokuto Seiyaku) to which 3% of the serum described

in Example 2 (1) had been added was used. The culture of hybridoma 1-3-1 was then charged into a Protein A-agarose column, and adsorbed antibody was then eluted out to obtain purified antibody 1-3-1. The antibody was confirmed to be a pure IgM by SDS-PAGE.

(2) Fluorescent Labeling of Antibody 1-3-1

The purified antibody 1-3-1 was labeled by FITC according to the method described in Example 2 (2). Absorbance of fractions containing labeled antibody was measured at $OD_{280nm}$ and $OD_{495nm}$, and labeling degree was determined. F/P ratio was 6.7.

Experiment 4

Study on Reactivity of Human Monoclonal Antibody to Cancer Cell Lines

(1) Cancer Cell Lines and Preservation thereof

Human colon cancer cell line C-1 and stomach cancer cell line MKN45 were preserved and grown at 37°C and 5% $CO_2$ conditions in Culture Medium B in the same manner as described in Experiment 1 (1).

(2) Study on Reactivity to Living Cancer Cell Lines

Cancer cells were cultured in a flask or Petri dish and culture supernatant was discarded. To the residue was added PBS solution containing 0.02% EDTA, and the mixture was left to stand at room temperature for 30

minutes allowing the cells to float. The cells were washed with Culture Medium B by centrifugation and suspended in PBS so as to make the cell density of about $1\times10^6$/200µl. Antibody 1-3-1 obtained in Example 5 (1) was added to the above solution to make the final concentration of the antibody of 50µg/ml, and the mixture was allowed to react at 0°C for 60 minutes. The suspension was centrifuged at 2000 rpm for 2 minutes and the supernatant was discarded. To the remaining cells was added FITC labeled anti-human antibody solution (200µl) (Capel) diluted with 1% BSA-containing PBS by 500 times, and the resulting cell suspension was kept at 0°C for 60 minutes. The suspension was centrifuged at 2000 rpm for 2 minutes to remove the supernatant, and the remaining cells was suspended in and washed with PBS (1ml) by centrifugation, and the cells were finally suspended in PBS (300µl) containing PI (10µg/ml). The resultant cell suspension was subjected to FCM, and magnitude of fluorescence (FITC and PI) bonded to particular cell was determined. The reactivities of antibody 1-3-1 to colon cancer cell line C-1 and stomach cancer cell line MKN45 are respectively shown in Figs. 3 and 4 of the accompanying drawings. In the figures, the abscissa shows fluorescence intensity per cancer cell and the ordinate shows the number of the cancer cells. As a control, a commercially available IgM antibody (Capel) was

used, and the reactivities of the IgM antibody to the above-identified cancer cells were determined. In the figures, the dotted line and solid line show the reactivities of antibody 1-3-1 and the control respectively. These figures show that antibody 1-3-1 has a strong binding ability to cancer cells.

Experiment 5

Reactivity of Human Monoclonal Antibody 1-3-1 to Cells Derived from Fresh Cancer Tissue and Non-Cancer Tissue

In order to study a binding specificity of antibody 1-3-1 to cancer cells, normal cells were simultaneously isolated from fresh tissue belonging to the same organ of the same patient, from which cancer cells were obtained, and reactivities of antibody 1-3-1 to respective cells were measured. Isolation of cells from the tissue was conducted according to Tokita's method as described in Experiment 3.

The reactivity to the cells obtained above was determined by FCM in the same manner as previously described in the living cancer cells. However, the cells were washed with Culture Medium B, suspended in serum derived from healthy volunteers, which serum contained fluorescent labeled antibody 1-3-1 (final concentration of 50μg/ml) prepared in Example 5 (2), to the cell density of about $1\times10^6$/200μl. The suspension was allowed to react at

0°C for 60 minutes and subjected to centrifugation at 2000 rpm for 2 minutes to remove the supernatant. The remaining cells were suspended in PBS (1ml) and washed by centrifugation. The cells were resuspended in PBS (300µl) containing PI (10µg/ml), and the suspension was subjected to FCM. The amount of fluorescent (FITC and PI) bonded to a particular cell was measured. Markers (5 species) for determining the amount of fluorescence (quantitative kit as previously prescribed) were subjected to FCM under the same condition. Average amount of FITC bonded to a single cell was calculated. Based on the average amount and F/P ratio of labeled antibody calculated in Example 5 (2), the average number of antibodies bonded to a living cancer cell was calculated. The results are shown in Table 4.

Table 4

| Antibody | Colon | | Stomach | |
|---|---|---|---|---|
| | Cancer Cells | Non-cancer Cells | Cancer Cells | Non-cancer Cells |
| 1-3-1 | $1.5 \times 10^4$ | $0.04 \times 10^4$ | $1.8 \times 10^3$ | $0.05 \times 10^3$ |
| Control | $0.15 \times 10^4$ | $0.04 \times 10^4$ | $0.2 \times 10^3$ | $0.3 \times 10^3$ |

The reactivity of the human monoclonal antibody 1-3-1 to non-cancer cells was the same level as, or less than, that of the antibody which was derived from

peripheral blood of healthy volunteers and fluorescent-labeled in the same manner as antibody 1-3-1, while the average number of antibodies bonded to cancer cells is remarkably higher than that in the non-cancer cells. In addition, the number of antibodies bonded to cancer cells was 10 times greater than that in the control antibody both in stomach and colon cancer. These results indicate that antibody 1-3-1 recognizes an antigen dominantly expressed on the surface of cell membrane of cancer cells.

Examples 6

(1) Determination of Subclass of Light Chain of Monoclonal Antibody 1-3-1

In order to determine the subclass of the light chain of antibody 1-3-1, the same procedure as described in Example 3 was repeated except that antibody 1-3-1 obtained in Example 5 (1) was used in place of antibody GAH. The light chain of antibody 1-3-1 reacted with anti-human λ chain antibody, which was detected through the appearance of coloured band. This revealed that the light chain was λ chain.

(2) Preparation of Gene Encoding Monoclonal Antibody 1-3-1 and Determination of Base Sequence

a. Preparation of cDNA encoding antibody 1-3-1 by means of PCR

According to the method detailed below, poly(A) containing RNAs were prepared from antibody 1-3-1 producing

hybridoma obtained in Example 4 (2) using guanidine thiocyanate-lithium chloride method (DNA 2 329, 1983).

In the same manner as described in Example 3 except that the number of hybridoma cells used was $2\times10^8$, the mRNA was prepared. The resultant RNAs (about 1.8mg) was dissolved in a solution (1ml) comprising 10mM Tris-HCl, pH8.0, and 1mM EDTA. A 230µl aliquot of the solution provided about 20µg of mRNA containing poly(A) after purification by means of mRNA Purification Kit (Pharmacia). Following the procedure described in Example 3, the poly(A)-containing mRNA (4.3µg) was dissolved in water (10µl), and to the solution were added oligo d(T) 12-18 primer (0.6µg), 10mM 4 dNTP (2µl), reverse transcriptase (40U), RNase inhibitor (30U), 5 × reverse transcriptase buffer (6µl), and additionally water to make a total volume of 30µl. The mixture was allowed to react at 42°C for one hour, followed by ethanol precipitation to obtain cDNA.

The cDNA thus obtained was dissolved in water (20µl). To the solution were added a 5 × terminal deoxynucleotide transferase buffer (5µl), terminal deoxynucleotide transferase (11U), and 10mM dGTP (2.5µl) to make a total volume of 25µl by adding water (6.5µl), and the mixture was allowed to react at 37°C for 1 hour to add poly d(G) at 3′ terminal of cDNA. After completion of the

reaction, the enzymes were inactivated by heating at 70°C for 10 minutes.

PCR was conducted using the cDNA thus obtained as a template. Thus, to the above reaction mixture (2.5µl) were added, as a primer for amplifying cDNA encoding variable region of the heavy chain, poly C (14 nucleotides) which hybridizes dG tail added to 3' terminal of the cDNA (25pmol), a single stranded DNA primer (17 nucleotides) corresponding to the base sequence of constant region of IgM shown in Sequence Listing No. 7 (25pmol) (Nucleic Acids Research 18 4278, 1990), poly C as a primer for amplifying cDNA encoding variable region of the light chain (25pmol), a single stranded DNA primer (19 nucleotides) (25pmol) corresponding to the base sequence of constant region of λ chain, shown in Sequence Listing No. 8 (Nature 294 536, 1981). The mixture was treated in the same manner as described in Example 3, which provided a double-stranded cDNA having blunt ends.

b. Determination of base sequence of cDNA

The cDNA solution obtained above was subjected to 2% agarose electrophoresis, and a band was observed at about 500bp. The band was cut away from the agarose gel. The cDNA was inserted into a cloning vector pUC119 at SmaI site, and the base sequence was determined by dideoxy method, which revealed that among total base sequence of

the PCR fragment, the base sequence encoding variable regions of the heavy and light chains were respectively those shown in Sequence Listing Nos. 9 and 10.

The amino acid sequences of variable regions of heavy and light chains of antibody 1-3-1 produced by the above-mentioned hybridoma were deduced from the base sequences determined above and are respectively shown in Sequence Listing Nos. 11 and 12. The DNA fragment, the base sequence of which has been determined, can be prepared by means of DNA synthesizer with good reproducibility, and therefore, the acquisition of the DNA fragment does not require the repetition of the above procedure.

Example 7

Preparation of Adriamycin-Containing Liposome Bonded to Antibody GAH

a. Preparation of Thiolated Antibody

Anti-cancer antibody GAH (IgG) was dissolved in 0.1M - acetate buffer (pH4.0), and pepsin (1/40 mol) (Cooper Biomedical) was added thereto. The mixture was allowed to react overnight to prepare $F(ab')_2$. Chromatography over cation-exchange resin (mono S) (Pharmacia) isolated $F(ab')_2$. The solvent used was a linear gradient of 0.1M - acetate buffer (pH4.0) containing 0-0.5M NaCl. To the isolated $F(ab')_2$ in 0.1M - acetate buffer (pH4.5) containing 0.15M NaCl was added DTT at a ratio of

(Nucleopore; Microscience) having a pore size of 200nm and kept at 60°C. Repeated pressure-filtration (10 times) gave a dressed liposome. The liposome solution was neutralized with addition of 1M NaOH solution, and to the neutral solution was added one tenth (by weight) of adriamycin (Kyowa Hakko) with respect to the lipid components while being kept at 60°C. More than 97% of adriamycin was positively enclosed into the liposome according to the pH slope between the inside and outside of the liposome to give a liposome into which adriamycin bearing maleimide group had been encapsulated.

e. Binding of maleimide group-bearing adriamycin-encapsulated liposome to thiolated antibody and PEG modification

To the adriamycin-encapsulated liposome obtained above (lipid components: 100mg) was added thiolated Fab' antibody (5mg), and the mixture was allowed to react at 37°C for 8 hours. To the reaction mixture was added thiolated PEG (5μmol), and the mixture was allowed to react in PBS at room temperature for 6 hours to obtain adriamycin-encapsulated liposome bonded to antibody and modified with PEG. The latter was further subjected to gel filtration using Sepharose C16B (Pharmacia) to remove non-reacted cysteine-binding PEG.

Experiment 6

Confirmation of Pharmaceutical Effectiveness of Adriamycin-Encapsulated Liposome Bonded to Antibody GAH and Modified with PEG

Study on anti-cancer effect of antibody GAH was conducted in the manner as described below using human stomach cancer cell line MKN45 which had shown reactivity to antibody GAH and accumulative behavior in transplantation to nude mouse.

Cultured MKN45 cells ($1\times10^6$) were subcutaneous-transplanted to nude mouse. Experiment started when the cancer weight became about 100μg after ten days from the transplantation (Fig. 5). Adriamycin-encapsulated liposome bonded to antibody GAH and modified with PEG was administered to mouse via caudal vein at a dose corresponding to 5mg/kg or adriamycin day 0, 3, 7 (shown by mark ◊ in Fig. 5). As a control, phosphate buffered physiological saline (shown by mark ♦), adriamycin (shown by mark □), and adriamycin-encapsulated liposome modified with PEG (shown by mark ×) were administered to mice (each 6-7 animals). Time-course measurement of growth of cancer was conducted by means of Battle-Columbus method wherein presumptive cancer weight was determined according to the formulation : (short diameter) × (short diameter) × (long diameter)/2, and compared with that determined at the beginning of the experiment.

In Fig. 5, the abscissa shows time-lapse (days) after beginning of the experiment, and the mark (↓) indicates the administration of the pharmaceutical formulation of the invention. Fig. 5 clearly shows that the formulation of the invention, adriamycin-encapsulated liposome bonded to antibody GAH, possesses potent anti-cancer effect. It is apparent, therefore, that human monoclonal antibodies of the invention allow continuous and long term "targeting therapy" of cancer tissue or organ with the help of anti-cancer agents or toxins.

(1) GENERAL INFORMATION:

(i) APPLICANT: Saiko HOSOKAWA
Toshiaki TAGAWA
Yoko HIRAKAWA
Norihiko ITO
Kazuhiro NAGAIKE

(ii) TITLE OF INVENTION: Human Monoclonal Antibody Specifically Binding to Surface Antigen of Cancer Cell Membrane

(iii) NUMBER OF SEQUENCES: 42

(2) INFORMATION FOR SEQ ID NO:1

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE: human IgG antibody

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

G GCC CTT GGT GGA GGC TGA AGA GAC GGT GAC CAT TCT 37

(2) INFORMATION FOR SEQ ID NO:2

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE: human IgG antibody

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGG TGC AGC CAC AGT TCG TTT 21

(2) INFORMATION FOR SEQ ID NO:3

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 357 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCA     45
CAG ACC CTG TCC CTC ACC TGC ACT GTC TCT GGT GGC TCC ATC AGC     90
AGT TGT GGT TTC TAC TGG AAC TGG ATC CGC CAG CAC CCA GGG AAG    135
GGC CTG GAG TGG ATT GGG TAC ATC TAT TAC AGT GGG AGC ACC TAC    180
TAC AAC CCG TCC CTC AAG AGT CGA GTT ACC ATA TCG CTA GAC ACG    225
TCT AAG AGC CAG TTC TCC CTG AAG CTG AGC TCT CTG ACT GCC GCG    270
GAC ACG GCC GTG TAT TAC TGT GCG AGG TCT ACC CGA CTA CGG GGG    315
GCT GAC TAC TGG GGC CAG GGA ACA ATG GTC ACC GTC TCT TCA        357
```

(2) INFORMATION FOR SEQ ID NO:4

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 342 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT GTG TCT CTG     45
GGC GAG AGG GCC ACC ATC AAC TGC AAG TCC AGC CAG AGT GTT TTA     90
TAC AAC TCC AAC AAT AAG AAA TAC TTA GCT TGG TAC CAG CAG AAA    135
CCA GGA CAG CCT CCT AAG CTG CTC ATT TAC TGG GCA TCT ACC CGG    180
```

```
GAA TCC GGG GTC CCT GAC CGA TTC AGT GGC AGC GGG TCT GGG ACA    225
GAT TTC ACT CTC ACC ATC AGC AGC CTG CAG GCT GAA GAT GTG GCA    270
GTT TAT TAC TGT CAG CAG TAT TAT AGT ACT CCG TGG ACG TTC GGC    315
CAA GGG ACC AAG GTG GAA ATC AAA CGA                           342
```

(2) INFORMATION FOR SEQ ID NO:5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 119 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser
  1               5                  10                  15
Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
                20                  25                  30
Ser Cys Gly Phe Tyr Trp Asn Trp Ile Arg Gln His Pro Gly Lys
                35                  40                  45
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr
                50                  55                  60
Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Leu Asp Thr
                65                  70                  75
Ser Lys Ser Gln Phe Ser Leu Lys Leu Ser Ser Leu Thr Ala Ala
                80                  85                  90
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Arg Leu Arg Gly
                95                 100                 105
Ala Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
               110                 115             119
```

(2) INFORMATION FOR SEQ ID NO:6

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 114 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu
 1               5                  10                  15
Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu
            20                  25                  30
Tyr Asn Ser Asn Asn Lys Lys Tyr Leu Ala Trp Tyr Gln Gln Lys
            35                  40                  45
Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
            50                  55                  60
Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
            65                  70                  75
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala
            80                  85                  90
Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly
            95                 100                 105
Gln Gly Thr Lys Val Glu Ile Lys Arg
           110                 114
```

(2) INFORMATION FOR SEQ ID NO:7
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE: human IgM antibody

TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC 360
TCC TCA 366

(2) INFORMATION FOR SEQ ID NO:10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 324 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TAT GAG CTG ACA CAG CCA CCC TCG GTG TCA GTG TCC CCA GGA CAG 45
ACG GCC AGG ATC ACC TGC TCT GGA GAT GCA TTG CCA AAG CAA TAT 90
GCT TAT TGG TAC CAG CAG AAG CCA GGC CAG GCC CCT GTG CTG GTG 135
ATA TAT AAA GAC AGT GAG AGG CCC TCA GGG ATC CCT GAG CGA TTC 180
TCT GGC TCC AGC TCA GGG ACA ACA GTC ACG TTG ACC ATC AGT GGA 225
GTC CAG GCA GAA GAC GAG GCT GAC TAT TAC TGT CAA TCA GCA GAC 270
AGC AGT GGT ACT TAT GAG GTA TTC GGC GGA GGG ACC AAG CTG ACC 315
GTC CTA GGT 324

(2) INFORMATION FOR SEQ ID NO:11

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser
 1               5                  10                  15
Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys
            35                  40                  45
Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr
            50                  55                  60
Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr
            65                  70                  75
Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala
            80                  85                  90
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Tyr Gly Gly Tyr
            95                 100                 105
Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
           110                 115                 120
Ser Ser
    122
```

(2) INFORMATION FOR SEQ ID NO:12

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
 1               5                  10                  15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr
```

```
                    20                  25                  30
Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val
                    35                  40                  45
Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe
                    50                  55                  60
Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly
                    65                  70                  75
Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp
                    80                  85                  90
Ser Ser Gly Thr Tyr Glu Val Phe Gly Gly Gly Thr Lys Leu Thr
                    95                  100                 105
Val Leu Gly
        108
```

(2) INFORMATION FOR SEQ ID NO:13

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
Ile Ser Ser Xaa Xab Xac Tyr Trp
  1               5
```

Xaa : Cys or Ser, Xab : Gly or Ser, Xac : Phe or Tyr

(2) INFORMATION FOR SEQ ID NO:14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ile Gly Xaa Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr
1 5 10

Xaa : Tyr or Ser,

(2) INFORMATION FOR SEQ ID NO:15
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Gly Xaa Asp Xab
1

Xaa : Ala or Met, Xab : Tyr or Val

(2) INFORMATION FOR SEQ ID NO:16
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Ile Ser Ser Cys Gly Phe Tyr Trp Asn
1 5

(2) INFORMATION FOR SEQ ID NO:17
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr
1 5 10

(2) INFORMATION FOR SEQ ID NO:18
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ser Thr Arg Leu Arg Gly Ala Asp Tyr

1 5

(2) INFORMATION FOR SEQ ID NO:19

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys Ser Ser Gln Ser Val Leu Tyr Asn Ser Asn Asn Lys Lys Tyr Leu Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Trp Ala Ser Thr Arg Glu Ser
1 5

(2) INFORMATION FOR SEQ ID NO:21

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Gln Gln Tyr Tyr Ser Thr Pro Trp Thr
1 5

(2) INFORMATION FOR SEQ ID NO:22
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody
1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp
1 5 10

(2) INFORMATION FOR SEQ ID NO:23
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody
1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:24
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Gly Ser Tyr Gly Gly Tyr Tyr Tyr Gly Met Asp Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:25
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Asp Ala Leu Pro Lys Gln Tyr Ala Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:26
(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Lys Asp Ser Glu
1

(2) INFORMATION FOR SEQ ID NO:27
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Gln Ser Ala Asp Ser Ser Gly Thr Tyr Glu Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:28
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:

(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATC AGC AGT WGT RGT TWC TAC TGG 28

W : T or A, R : G or A

(2) INFORMATION FOR SEQ ID NO:29

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATT GGG WRY ATC TAT TAY AGT GGG AGC ACC TAC TAC 36

W : T or A, R : A or G, Y : C or T

(2) INFORMATION FOR SEQ ID NO:30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: hybridoma producing human monoclonal antibody, an antigen to which exists on the surface of cancer cell membrane

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGK RYK GAC KWC 12

K : G or T, R : G or A, Y : C or T
W : A or T

(2) INFORMATION FOR SEQ ID NO:31
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

ATC AGC AGT TGT GGT TTC TAC TGG 27

(2) INFORMATION FOR SEQ ID NO:32
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATT GGG TAC ATC TAT TAC AGT GGG AGC ACC TAC TAC 36

(2) INFORMATION FOR SEQ ID NO:33
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TCT ACC CGA CTA CGG GGG GCT GAC TAC 27

(2) INFORMATION FOR SEQ ID NO:34
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AAG TCC AGC CAG AGT GTT TTA TAC AAC TCC AAC AAT AAG AAA TAC TTA GCT 51

(2) INFORMATION FOR SEQ ID NO:35
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody GAH
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TGG GCA TCT ACC CGG GAA TCC 21

(2) INFORMATION FOR SEQ ID NO:36

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody GAH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CAG CAG TAT TAT AGT ACT CCG TGG ACG 27

(2) INFORMATION FOR SEQ ID NO:37

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody

1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATC AGC AGT AGT AGT TAC TAC TGG GGC TGG 30

(2) INFORMATION FOR SEQ ID NO:38

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

ATT GGG AGT ATC TAT TAT AGT GGG AGC ACC TAC TAC AAC CCG 42

(2) INFORMATION FOR SEQ ID NO:39

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GGG AGC TAC GGG GGC TAC TAC TAC GGT ATG GAC GTC 36

(2) INFORMATION FOR SEQ ID NO:40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(G) CELL TYPE: Hybridoma producing human antibody 1-3-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GAT GCA TTG CCA AAG CAA TAT GCT TAT 27

(2) INFORMATION FOR SEQ ID NO:41

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AAA GAC AGT GAG 12

(2) INFORMATION FOR SEQ ID NO:42
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(G) CELL TYPE: Hybridoma producing human antibody 1-3-1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CAA TCA GCA GAC AGC AGT GGT ACT TAT GAG GTA 33

What is claimed is:

1. A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, said antibody being produced by a hybridoma obtained by cell fusion between human lymphocytes derived from cancer patient and mouse myeloma cells.

2. The human monoclonal antibody of Claim 1 wherein the variable region of the heavy chain of the antibody contains the amino acid sequences in Sequence Listing Nos. 13, 14, and 15.

3. The human monoclonal antibody of Claim 1 wherein the variable regions of the heavy and light chains of the antibody contain the amino acid sequences in Sequence Listing Nos. 16, 17, and 18, and 19, 20, and 21, respectively.

4. The human monoclonal antibody of Claim 1 wherein the variable regions of the heavy and light chains of the antibody are represented by the amino acid sequences in Sequence Listing Nos. 5 and 6 respectively.

5. The human monoclonal antibody of Claim 1 wherein the variable regions of the heavy and light chains of the antibody contain the amino acid sequences in Sequence Listing Nos. 22, 23, and 24, and 25, 26, and 27, respectively.

6. The human monoclonal antibody of Claim 1 wherein the variable regions of the heavy and light chains of the antibody are represented by the amino acid sequences in Sequence Listing Nos. 11 and 12 respectively.

7. An isolated DNA encoding the monoclonal antibody of Claim 1.

8. An isolated DNA encoding the monoclonal antibody of Claim 2.

9. The isolated DNA of Claim 8 wherein partial DNAs encoding the variable region of the heavy chain contains the base sequences in Sequence Listing Nos. 28, 29, and 30.

10. An isolated DNA encoding the monoclonal antibody of Claim 3.

11. The isolated DNA of Claim 10 wherein partial DNAs encoding the variable regions of the heavy and light chains of the antibody contain the base sequences in Sequence Listing Nos. 31, 32, and 33, and 34, 35, and 36, respectively.

12. An isolated DNA encoding the monoclonal antibody of Claim 4.

13. The isolated DNA of Claim 12 wherein partial DNAs encoding the variable regions of the heavy and light chains of the antibody are represented by the base sequences in Sequence Listing Nos. 3 and 4 respectively.

14. An isolated DNA encoding the monoclonal antibody of Claim 5.

15. The isolated DNA of Claim 14 wherein partial DNAs encoding the variable regions of the heavy and light chains of the antibody contain the base sequences in Sequence Listing Nos. 37, 38, and 39, and 40, 41, and 42, respectively.

16. An isolated DNA encoding the monoclonal antibody of Claim 6.

17. The isolated DNA of Claim 16 wherein partial DNAs encoding the variable regions of the heavy and light chains of the antibody are represented by the base sequences in Sequence Listing Nos. 9 and 10 respectively.

18. A hybridoma producing the monoclonal antibody of Claim 1.

19. A hybridoma producing the monoclonal antibody of Claim 2.

20. A hybridoma producing the monoclonal antibody of Claim 3.

21. A hybridoma producing the monoclonal antibody of Claim 4.

22. A hybridoma producing the monoclonal antibody of Claim 5.

23. A hybridoma producing the monoclonal antibody of Claim 6.

24. An anti-cancer formulation comprising the monoclonal antibody of Claim 1, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

25. An anti-cancer formulation comprising the monoclonal antibody of Claim 2, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

26. An anti-cancer formulation comprising the monoclonal antibody of Claim 3, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

27. An anti-cancer formulation comprising the monoclonal antibody of Claim 4, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

28. An anti-cancer formulation comprising the monoclonal antibody of Claim 5, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

29. An anti-cancer formulation comprising the monoclonal antibody of Claim 6, said antibody being bonded to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells.

Abstract of the Disclosure:

A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.

FIG. 1


EcoRI
SV40
pro.
PstI
pKCRH2
β-globin
EcoRI
HindIII
EcoRI
SV40ter.
SalI
EcoRI
HindIII
Ligase reaction
EcoRI
SV40
pro.
PstI
pKCR/H
β-globin
HindIII
SV40ter.
SalI
(ΔEcoRI)
Blunt
SV40
pro.
PstI
HindIII
SV40ter.
SalI
EcoRI
PstI
ΔEcoRI
PstI
EcoRI
pKCRD
ΔSalI/
ΔEcoRI
SalI
HindIII

FIG. 2


EcoRI
SV40
pro.
PstI
pKCRH2
β-globin
EcoRI
HindIII
EcoRI
SV40ter.
SalI
EcoRI
Ligase
reaction
ΔEcoRI
SV40
pro.
PstI
pKCR(ΔE)
β-globin
EcoRI
HindIII
EcoRI
SV40ter.
SalI
EcoRI
HindIII
Ligase reaction
EcoRI
Ligase reaction
ΔEcoRI
SV40
pro.
PstI
pKCR(ΔE)/H
β-globin
HindIII
SV40ter.
SalI
ΔEcoRI
SV40
pro.
PstI
pKCR(ΔE)/E
β-globin
EcoRI
SV40ter.
SalI
SalI
PstI
ΔEcoRI
SV40
pro.
PstI
β-globin
EcoRI
SV40ter.
Blunt
(ΔSalI)
ΔEcoRI
PstI
EcoRI
pKCRD
ΔSalI/
ΔEcoRI
SalI
HindIII

FIG. 3


250
NUMBER
OF CELLS
0
FLUORESCENCE INTENSITY

FIG. 4


250
NUMBER
OF CELLS
0
FLUORESCENCE INTENSITY

*FIG. 5*



Rev. 3-3/7/88 Effective March 7, 1988

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

(X) Original ( ) Supplemental ( ) Substitute ( ) PCT ( ) DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: HUMAN MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO SURFACE ANTIGEN OF CANCER CELL MEMBRANE

which is described and claimed in:
(X) the attached specification, or
( ) the specification in the application Serial No. _____ filed _____;
and with amendments through _____ (if applicable).
( ) the specification in International Application No. PCT/_____, filed _____, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

| COUNTRY | APPLICATION NO. | DATE OF FILING | PRIORITY CLAIMED |
|---|---|---|---|
| Japan | 158859/1991 | June 28, 1991 | (X) YES ( ) NO |
| Japan | 158860/1991 | June 28, 1991 | (X) YES ( ) NO |
| Japan | 158861/1991 | June 28, 1991 | (X) YES ( ) NO |
| | | | ( ) YES ( ) NO |
| | | | ( ) YES ( ) NO |
| | | | ( ) YES ( ) NO |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| SERIAL NO. | U.S. FILING DATE | STATUS |
|---|---|---|
| | | ( ) Patented ( ) Pending ( ) Abandoned |
| | | ( ) Patented ( ) Pending ( ) Abandoned |
| | | ( ) Patented ( ) Pending ( ) Abandoned |

And I hereby appoint V. M. Creedon, Reg. No. 17111, John T. Miller, Reg. No. 21120, John T. Fedigan, Reg. No. 24347, Michael R. Davis, Reg. No. 25134, Matthew M. Jacob, Reg. No. 25154, Jeffrey Nolton, Reg. No. 25408, and Henry M. Zykorie, Reg. No. 27477, who together constitute the firm of WENDEROTH, LIND & PONACK, jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Send Correspondence to:

WENDEROTH, LIND & PONACK
Southern Building - Suite 700
805 Fifteenth Street, N.W.
Washington, D.C. 20005

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK
Area Code (202) 371-8850

"The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from _____ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned."

Effective March 7, 1988

| | | | |
|---|---|---|---|
| FULL NAME OF 1ST INVENTOR | FAMILY NAME: HOSOKAWA | FIRST GIVEN NAME: Saiko | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: Kawasaki-shi | STATE OR COUNTRY: Kanagawa-ken | COUNTRY OF CITIZENSHIP: Japan |
| POST OFFICE ADDRESS | ADDRESS: 1458-25, Okagami, Aso-ku, Kawasaki-shi, Kanagawa-ken, Japan | CITY: | STATE OR COUNTRY: ZIP CODE: |
| FULL NAME OF 2ND INVENTOR | FAMILY NAME: TAGAWA | FIRST GIVEN NAME: Toshiaki | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: Yokohama-shi | STATE OR COUNTRY: Kanagawa-ken | COUNTRY OF CITIZENSHIP: Japan |
| POST OFFICE ADDRESS | ADDRESS: 3-A102, Sakuradai, Midori-ku, Yokohama-shi, Kanagawa-ken, Japan | CITY: | STATE OR COUNTRY: ZIP CODE: |
| FULL NAME OF 3RD INVENTOR | FAMILY NAME: HIRAKAWA | FIRST GIVEN NAME: Yoko | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: Yokohama-shi | STATE OR COUNTRY: Kanagawa-ken | COUNTRY OF CITIZENSHIP: Japan |
| POST OFFICE ADDRESS | ADDRESS: 1-23-1-203, Utsukushigaoka, Midori-ku, Yokohama-shi, Kanagawa-ken, Japan | CITY: | STATE OR COUNTRY: ZIP CODE: |
| FULL NAME OF 4TH INVENTOR | FAMILY NAME: ITO | FIRST GIVEN NAME: Norihiko | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: Yokohama-shi | STATE OR COUNTRY: Kanagawa-ken | COUNTRY OF CITIZENSHIP: Japan |
| POST OFFICE ADDRESS | ADDRESS: 23-4, Tana-cho, Midori-ku, Yokohama-shi, Kanagawa-ken, Japan | CITY: | STATE OR COUNTRY: ZIP CODE: |
| FULL NAME OF 5TH INVENTOR | FAMILY NAME: NAGAIKE | FIRST GIVEN NAME: Kazuhiro | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: Sagamihara-shi | STATE OR COUNTRY: Kanagawa-ken | COUNTRY OF CITIZENSHIP: Japan |
| POST OFFICE ADDRESS | ADDRESS: 5-7, Sakae-cho, Sagamihara-shi, Kanagawa-ken, Japan | CITY: | STATE OR COUNTRY: ZIP CODE: |
| FULL NAME OF 6TH INVENTOR | FAMILY NAME: | FIRST GIVEN NAME: | SECOND GIVEN NAME: |
| RESIDENCE & CITIZENSHIP | CITY: | STATE OR COUNTRY: | COUNTRY OF CITIZENSHIP: |
| POST OFFICE ADDRESS | ADDRESS: | CITY: | STATE OR COUNTRY: ZIP CODE: |

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Saiko Hosokawa Date May 11, 1992
Saiko HOSOKAWA

2nd Inventor Toshiaki Tagawa Date May 11, 1992
Toshiaki TAGAWA

3rd Inventor Yoko Hirakawa Date May 11, 1992
Yoko HIRAKAWA

4th Inventor Norihiko Ito Date May 11, 1992
Norihiko ITO

5th Inventor Kazuhiro Nagaike Date May 11, 1992
Kazuhiro NAGAIKE

6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U. S. Application Serial No. ....., Filing Date .....

Applicant Reference Number ....., Atty Docket No. .....

Title of Invention .....

.....